Understanding The Role of CYP51A1P2 in Drug Metabolism (G83530)

Target Name: CYP51A1P2

NCBI ID: G83530

CYP51A1P2

Other Name(s): cytochrome P450 family 51 subfamily A member 1 pseudogene 2 | CYP51P2 | Cytochrome P450 family 51 subfamily A member 1 pseudogene 2

Understanding The Role of CYP51A1P2 in Drug Metabolism

CYP51A1P2, also known as cytochrome P450 family 51 subfamily A member 1 pseudogene 2, is a gene that codes for a protein known as CYP51A1P2. This gene is a member of the cytochrome P450 family 51, which is a well-known gene family that is involved in the metabolism of a wide variety of drugs and other molecules.

CYP51A1P2 is a pseudogene, which means that it is a genetic sequence that is present in the genome but does not code for a functional protein. This gene is thought to have evolved from a ancestral gene that was involved in the metabolism of drugs, but it has lost the ability to function as a gene product.

The CYP51A1P2 gene is located on chromosome 16 at position 12.2. It is a small gene that contains only a few amino acid residues. The protein produced by this gene is known to be a key regulator of the metabolism of many drugs, including statins, antidepressants, and beta blockers.

One of the functions of CYP51A1P2 is to act as a negative regulator of the metabolism of drugs that are metabolized by the liver enzyme CYP3A4. CYP3A4 is a well-known gene that is involved in the metabolism of many drugs, including many statins, antidepressants, and beta blockers. By acting as a negative regulator of CYP3A4, CYP51A1P2 helps to prevent the production of too much of these drugs, which can be harmful.

Another function of CYP51A1P2 is to act as a positive regulator of the metabolism of the drug atorvastatin, which is used to treat hyperlipidemia (elevated cholesterol levels). Atorvastatin is metabolized by CYP3A4, but CYP51A1P2 can help to increase its metabolism by promoting the production of an intermediate metabolite that is less potent.

CYP51A1P2 is also involved in the metabolism of other drugs, including rosuvastatin, ezetimibe, and nifedipine. It is thought to play a similar role in the metabolism of these drugs as it does with atorvastatin and other statins.

In addition to its role in drug metabolism, CYP51A1P2 is also thought to be involved in the regulation of other processes in the body. For example, it has been shown to be involved in the metabolism of xenobiotics, which are synthetic molecules that are used to treat a wide range of diseases and disorders.

Despite its importance in the metabolism of drugs, CYP51A1P2 is not a drug target itself. This means that it does not have any known targets that can be targeted by drugs or other molecules. However, its role in the metabolism of drugs makes it a potential biomarker for drug-induced liver injury (DILI) and other adverse events associated with statin use.

The study of CYP51A1P2 and its function as a drug target is an active area of research, and many scientists are interested in understanding more about its role in the metabolism of drugs and how it might be targeted by drugs or other molecules. In the future, studies on CYP51A1P2 and its function as a drug target may help to improve our understanding of how drugs work and how they can be used to treat a wide range of diseases and disorders.

Protein Name: Cytochrome P450 Family 51 Subfamily A Member 1 Pseudogene 2

The "CYP51A1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP51A1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets